This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease


Sato, Tomohiko, Hanyu, Haruo, Hirao, Kentaro, Kanetaka, Hidekazu, Sakurai, Hirofumi, Iwamoto, Toshihiko


Neurobiology Of Aging, Volume: 32, No.: 9, Pages.: 1626-1633

Year of Publication



To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus. We randomly assigned 42 patients to either the group treated with 15-30 mg pioglitazone daily (n=21, pioglitazone group) or not (n=21, control group). The pioglitazone group improved cognition and rCBF in the parietal lobe, while the control group showed no such improvement. The plasma Aβ40/Aβ42 ratio increased in the control group, but showed no significant change in the pioglitazone group. Both groups showed good control of diabetes during the study. In addition, pioglitazone treatment resulted in a decrease in fasting plasma insulin levels, indicating enhanced insulin sensitivity. The results of this pilot study demonstrated that pioglitazone exhibited cognitive and functional improvements, and stabilization of the disease in diabetic patients with AD. Pioglitazone may offer a novel strategy for the treatment of AD.; Copyright © 2009 Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Sato_2011, doi = {10.1016/j.neurobiolaging.2009.10.009}, url = {}, year = 2011, month = {sep}, publisher = {Elsevier {BV}}, volume = {32}, number = {9}, pages = {1626--1633}, author = {Tomohiko Sato and Haruo Hanyu and Kentaro Hirao and Hidekazu Kanetaka and Hirofumi Sakurai and Toshihiko Iwamoto}, title = {Efficacy of {PPAR}-$upgamma$ agonist pioglitazone in mild Alzheimer disease}, journal = {Neurobiology of Aging} }


aged, aged, 80 and over, agonists, alzheimer disease, cognition disorders, diabetes mellitus type 2, drug therapy, female, humans, male, metabolism, physiology, pilot projects, pioglitazone, ppar gamma, therapeutic use, thiazolidinediones

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions